Drug delivery device and medical device

Abstract

The utility model relates to the technical field of medical instruments, in particular to a medicine delivery device and a medical device.The medicine delivery device comprises an inner tube, an outer tube and a branch tube, an expandable unit is arranged at the far end of the inner tube, and a delivery port is formed in the expandable unit; the inner tube is sleeved with the outer tube, a gap between the outer tube and the inner tube forms a conveying cavity channel, the far end of the outer tube penetrates through the near end of the expandable unit, the end face of the far end of the outer tube corresponds to the middle of the expandable unit, and the far end of the conveying cavity channel is communicated with the interior of the expandable unit; the branch pipe is communicated with the near end of the conveying cavity channel. Fluid is directly guided into the middle of the interior of the expandable unit through the conveying cavity channel and diffused to the periphery from the middle of the interior of the expandable unit, so that the flowing strokes of the fluid reaching the near end of the expandable unit and the far end of the expandable unit are close, and the difference of the fluid outlet amount of the near end of the expandable unit and the fluid outlet amount of the far end of the expandable unit is reduced; and uniform liquid discharge on the expandable unit is realized.

Description

Technical Field

[0001] This utility model relates to the field of vascular treatment technology, and in particular to a drug delivery device and a medical device. Background Technology

[0002] Drug-eluting catheters are a method for treating atherosclerotic diseases. They consist of an inner tube, an outer tube, and a balloon. By creating micropores on the balloon surface, therapeutic drugs are delivered from the proximal end of the catheter to the distal end of the balloon, forcing the balloon to inflate and adhere to the vessel wall corresponding to the target lesion. The therapeutic drug is then delivered to the target lesion site through the micropores on the balloon. When the photosensitive cross-linking agent in the drug rapidly penetrates into the vessel wall and promotes the cross-linking of collagen and elastin under photoexcitation, a scaffold is formed in situ, achieving vascular healing and repair, thus achieving a therapeutic effect. However, in the process of developing this invention, the applicant discovered that existing drug-eluting catheters suffer from uneven fluid output from the micropores on the balloon, affecting the therapeutic effect. Utility Model Content

[0003] The purpose of this application is to provide a drug delivery device and a medical device to solve the aforementioned technical problems existing in the prior art, mainly including the following two aspects:

[0004] The first aspect of this application provides a drug delivery device, including...

[0005] An inner tube, the distal end of which is provided with an expandable unit, and the expandable unit is provided with a conveying port;

[0006] The outer tube is sleeved on the inner tube, and the gap between the outer tube and the inner tube forms a delivery cavity. The distal end of the outer tube penetrates the proximal end of the expandable unit, and the distal end face of the outer tube corresponds to the middle part of the expandable unit. The distal end of the delivery cavity is connected to the interior of the expandable unit.

[0007] A branch pipe, which is connected to the proximal end of the delivery cavity.

[0008] Furthermore, the delivery port is a plurality of micropores disposed on the expandable unit.

[0009] Furthermore, the pore size of the micropores is 2μm to 100μm.

[0010] Furthermore, the density of micropores on the expandable unit is 0.5 pores / cm². 2 ~500 holes / cm 2 .

[0011] Furthermore, the outer tube has a buffer cavity at its proximal end, and the branch tube is connected to the proximal end of the delivery channel through the buffer cavity.

[0012] Furthermore, the cross-section of the buffer cavity is a closed annular structure or a semi-closed annular structure;

[0013] And / or, the cross-section of the delivery cavity is a closed annular structure or a semi-closed annular structure.

[0014] Furthermore, a mixing chamber is provided on the branch pipe, and a piston is provided inside the mixing chamber.

[0015] Furthermore, a three-way valve is provided on the branch pipe, and the three-way valve is located between the mixing chamber and the buffer chamber.

[0016] A second aspect of this application provides a medical device including the aforementioned drug delivery device.

[0017] This utility model has at least the following technical advantages over the prior art:

[0018] This invention utilizes a delivery channel to directly introduce fluid into the center of the expandable unit, allowing it to diffuse outwards from the center. This results in similar flow paths for the fluid to reach the near and far ends of the expandable unit. Furthermore, the flow path for the fluid to fill the entire expandable unit is reduced by half compared to existing technologies. This reduces the difference in fluid output between the near and far ends of the expandable unit, achieving uniform fluid output across the expandable unit. Attached Figure Description

[0019] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments of the present invention or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0020] Figure 1 This is a schematic diagram of the structure of the drug delivery device of this utility model (expandable unit before expansion);

[0021] Figure 2 This is a schematic diagram of the structure of the drug delivery device of this utility model (expandable unit after expansion);

[0022] Figure 3 This is a side view of the drug delivery device of this utility model;

[0023] Figure 4 yes Figure 3 Sectional view along line AA;

[0024] Figure 5 yes Figure 4 A magnified view of a section at point B in the middle;

[0025] Figure 6This is a schematic diagram of the internal structure of the expandable unit of this utility model;

[0026] Figure 7 This is another structural schematic diagram of the drug delivery device of this utility model;

[0027] Figure 8 This is a schematic diagram of the internal structure of the mixing chamber of this utility model;

[0028] In the picture,

[0029] 10. Inner tube; 20. Outer tube; 210. Delivery channel; 30. Expandable unit; 310. Micropore; 40. Branch tube; 50. Buffer chamber; 60. Mixing chamber; 610. Piston; 70. Three-way valve; 710. First port; 720. Second port; 730. Third port. Detailed Implementation

[0030] The following description provides many different embodiments or examples for implementing various features of the invention. The elements and arrangements described in the specific examples below are only for concise expression of the invention and are merely examples, not intended to limit the invention.

[0031] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the claimed invention, but merely to represent selected embodiments of the invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0032] In this invention, unless otherwise explicitly specified and limited, the terms "installation," "connection," "linking," and "fixing," etc., should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances. Furthermore, the terms "first," "second," etc., are used only for distinguishing descriptions and should not be construed as indicating or implying relative importance.

[0033] In this invention, unless otherwise expressly specified and limited, "above or below" a first feature may include direct contact between the first and second features, or contact between the first and second features through another feature between them. Furthermore, "above," "over," and "on" the first feature includes the first feature directly above or diagonally above the second feature, or simply indicates that the first feature is at a higher horizontal level than the second feature. "Below," "below," and "under" the first feature includes the first feature directly below or diagonally below the second feature, or simply indicates that the first feature is at a lower horizontal level than the second feature.

[0034] Furthermore, in this invention, "proximal end" and "distal end" refer to the near and far positions of the structure relative to human operation in the usage environment, in order to facilitate the description of the positional relationship between components and to facilitate understanding; for the same component, "proximal end" and "distal end" are relative positional relationships of the component, not absolute ones; therefore, they should be understood from the perspective of realizing the principle of this invention, and should not deviate from the essence of this invention.

[0035] Drug-eluting catheters are a method for treating atherosclerotic diseases. They consist of an inner tube, an outer tube, and a balloon. By creating micropores on the balloon surface, therapeutic drugs are delivered from the proximal end of the drug-eluting catheter to the distal end of the balloon, forcing the balloon to inflate and adhere to the vessel wall corresponding to the target lesion. The therapeutic drug is then delivered to the target lesion site through the micropores on the balloon, achieving a therapeutic effect. For existing drug-eluting catheters, such as the shockwave-assisted drug perfusion balloon catheter and medical device disclosed in Chinese Patent Publication No. CN215386905U, the drug delivery channel between the inner and outer tubes is connected to the proximal end of the balloon. When using this channel to infuse fluid into the balloon, the relatively long balloon can lead to differences in fluid output between the proximal and distal ends, or even complete fluid loss at the distal end. To address this uneven fluid output problem, this application provides a drug delivery device and medical device that can improve the uniformity of drug distribution within the balloon, as illustrated in the following embodiment.

[0036] Example 1:

[0037] This application provides a drug delivery device, such as... Figure 1 As shown, including

[0038] The inner tube 10 has an expandable unit 30 at its distal end. The inner tube 10 is used to guide the expandable unit 30 through a guidewire into the lesion area of ​​the patient's arteries, veins, lacrimal ducts, airways, nasal cavity, esophagus, bile duct, urethra, or other vascular or non-vascular cavities. Figures 1-4As shown, the expandable unit 30 is provided with a delivery port. When the expandable unit 30 is filled with fluid, the external volume of the expandable unit 30 increases with the volume of the fluid inside the expandable unit 30 (in this embodiment, the fluid is a fluid containing nanomedicine, which can be one of gas, liquid, solid, or a combination of at least two, preferably liquid) until the volume of the expandable unit 30 increases to the upper limit of volume expansion. At this time, the expandable unit 30 abuts against the inner wall of the blood vessel or maintains a preset gap between the expandable unit 30 and the inner wall of the blood vessel, and the fluid can accompany the expandable unit. The expansion unit 30 expands from the delivery port during the volume increase process. For example, the delivery port is directly connected to the interior of the expandable unit 30. The fluid can also flow out from the delivery port after the expandable unit 30 has expanded to a preset volume or preset shape. For example, a diaphragm is provided on the inner wall of the delivery port to separate the delivery port from the interior of the expandable unit 30. The diaphragm deforms and ruptures when the expandable unit 30 expands to a preset volume or preset shape, and the delivery port is connected to the interior of the expandable unit 30. The fluid inside the expandable unit 30 can then flow from the interior of the expandable unit 30 to the delivery port and flow out from the delivery port.

[0039] Outer tube 20, which is sleeved on inner tube 10, such as Figure 4 , Figure 5 and Figure 6 As shown, the gap between the outer tube 20 and the inner tube 10 forms a delivery cavity 210. The distal end of the outer tube 20 penetrates the proximal end of the expandable unit 30, and the distal end face of the outer tube 20 corresponds to the middle part of the expandable unit 30. The distal end of the delivery cavity 210 is connected to the interior of the expandable unit 30.

[0040] Branch pipe 40, which is connected to the proximal end of delivery cavity 210.

[0041] In use, since the distal end of the outer tube 20 penetrates the proximal end of the expandable unit 30 and corresponds to the middle of the expandable unit 30, the distal end of the delivery channel 210 is connected to the middle of the expandable unit 30. The fluid can directly enter the middle of the expandable unit 30 through the delivery channel 210 and diffuse from the middle of the expandable unit 30 to the surrounding areas. This makes the flow path of the fluid reaching the proximal end and the distal end of the expandable unit 30 similar. Moreover, the flow path of the fluid filling the entire expandable unit 30 is shortened by half compared to the prior art, thereby reducing the difference in fluid output between the proximal end and the distal end of the expandable unit 30 and achieving uniform fluid output on the expandable unit 30.

[0042] To achieve uniform fluid ejection from the expandable unit 30, the delivery port can be configured as multiple micropores 310 located on the expandable unit 30. Preferably, the multiple micropores 310 are located on the peripheral wall of the expandable unit 30. The fluid flows out from the distal end of the branch tube 40 and then flows sequentially through the delivery channel 210, the expandable unit 30, and the micropores 310 towards the inner wall of the blood vessel, allowing the fluid to be directly sprayed onto the inner wall of the blood vessel. Under reasonable control of the driving pressure of the pressure source, the fluid ejected from the micropores 310 can force the inner wall of the blood vessel to expand when it comes into contact with the inner wall of the blood vessel, allowing the fluid to more easily pass through the inner layer of the inner wall of the blood vessel and enter the middle layer and even the outer layer of the inner wall of the blood vessel. When the fluid contains a drug, the drug can reach the middle and outer layers of the inner wall of the blood vessel. When the fluid contains a photosensitive crosslinking agent and silk fibroin, the photosensitive crosslinking agent, under the excitation of the laser, will promote the silk fibroin to interpenetrate and crosslink with the collagen in the middle and outer layers to form a scaffold, thereby further improving the stability and safety of the scaffold structure and improving the therapeutic effect.

[0043] To achieve fluid ejection from the micropores 310, the pore size of the micropores 310 can be set to 2μm to 100μm, preferably 5μm to 50μm. In some embodiments, the pore size of the micropores 310 can also be set to 5μm to 20μm, thereby increasing the ejection pressure and ejection velocity of the fluid from the micropores 310. Preferably, by pressurizing, the fluid containing the drug is transferred to the blood vessel wall. The high-pressure jet can overcome the barriers of plaque and some calcified lesions at the lesion site. Compared with drug-coated balloons, it improves the drug transfer efficiency, while avoiding drug delivery loss and the generation of drug particles, thus reducing distal vascular embolism and systemic toxicity.

[0044] Specifically, the density of micropores 310 on the expandable unit 30 can be set to 0.5 pores / cm². 2 ~500 holes / cm 2 The nano-drug fluid is sprayed onto the inner wall of the body cavity through the micropores 310, allowing the drug fluid to be evenly transferred to the lesion site, avoiding excessive drug concentration at the lesion site, which could cause toxicity or insufficient treatment due to geographical absence of the lesion.

[0045] Furthermore, for existing drug dilators (such as the shockwave-assisted drug perfusion balloon catheter and medical device disclosed in Chinese Patent Publication No. CN215386905U), since the second interface and outer tube generally adopt a Y-shaped structure, based on the design of the inner and outer tubes, when the fluid enters the outer tube from the second interface, due to the influence of the fluid's own inertia and the obstruction of the inner tube, the fluid velocity on the side closer to the second interface is greater than that on the side farther from the second interface. When the fluid flows to the balloon and is ejected, it causes a difference in the outflow pressure on both sides of the balloon, resulting in uneven outflow of fluid from the micropores on the balloon. To improve the uniformity of outflow from the balloon, a buffer cavity 50 can be set at the proximal end of the outer tube 20. The fluid flows into the buffer cavity 50 from the branch tube 40 first, and then flows evenly to the delivery channel 210 through the buffer cavity 50. The buffer chamber 50 facilitates the transition of fluid flow between the branch tube 40 and the delivery channel 210, allowing the fluid to first fill the buffer chamber 50 before flowing evenly into the delivery channel 210. This reduces the velocity difference between the two sides of the inner tube, mitigating the uneven fluid output from the delivery port on the expandable unit 30 caused by the velocity difference. The fluid flows evenly from the delivery channel 210 into the expandable unit 30 and is sprayed onto the vascular wall through the delivery port. The silk fibroin in the drug (containing therapeutic drugs and silk fibroin) rapidly binds to collagen in the vascular wall under the initiation of a photosensitive crosslinking agent (contained in the fluid), forming a scaffold in situ, achieving vascular healing and repair, and thus achieving a therapeutic effect. The proximal end of the outer tube 20 is sealed to the proximal end of the inner tube 10 to ensure stable fluid flow along the delivery channel 210 to the expandable unit 30.

[0046] Correspondingly, a branch pipe 40 can be connected to the proximal end of the delivery channel 210 via a buffer chamber 50, allowing fluid to flow through the branch pipe 40 to the buffer chamber 50. When it is necessary to drive fluid flow to the expandable unit 30, the proximal end of the branch pipe 40 can be connected to a pressure source, generating driving pressure and creating a pressure difference between the proximal end of the branch pipe 40 and the output port. Under the action of this pressure difference, fluid is forced to flow between the branch pipe 40, the buffer chamber 50, the delivery channel 210, the expandable unit 30, and the delivery port. It should be noted that the pressure source can be a gas source or a liquid source, preferably a liquid source for pressurization, to avoid the risk of air embolism.

[0047] To improve the uniformity of fluid flow in the delivery cavity 210, the inner tube 10 and the outer tube 20 can be coaxially arranged so that the cross-section of the delivery cavity 210 has a uniform annular structure and the fluid has the same flow rate in different radial directions of the inner tube 10. Correspondingly, the cross-section of the buffer cavity 50 can be set as a closed annular structure so that the buffer cavity 50 can be adapted to the delivery cavity 210 with a corresponding closed annular structure.

[0048] In some embodiments, the inner tube 10 and the outer tube 20 can be arranged non-coaxially. Specifically, the inner tube 10 can be arranged away from the branch pipe 40. Correspondingly, the flow cross-sectional area of ​​the side of the conveying cavity 210 away from the branch pipe 40 is smaller than the flow cross-sectional area of ​​the side of the conveying cavity 210 close to the branch pipe 40. As a result, due to the change in diameter between the buffer cavity 50 and the conveying cavity 210, the fluid velocity gain on the side of the conveying cavity 210 away from the branch pipe 40 is greater than the fluid velocity gain on the side of the conveying cavity 210 close to the branch pipe 40. This offsets the fluid velocity gain caused by the fluid flowing towards the side of the conveying cavity 210 close to the branch pipe 40 due to its own inertia, so that the fluid velocity gain on both sides of the conveying cavity 210 is balanced or similar, thereby further improving the fluid outflow uniformity of the expandable unit 30. Correspondingly, the cross-section of the buffer cavity 50 can be set as a semi-closed annular structure so that the buffer cavity 50 can be adapted to the corresponding semi-closed annular structure of the conveying cavity 210.

[0049] In some implementations, the inner tube 10 and the outer tube 20 can be set non-coaxially. Specifically, the inner tube 10 can be set close to the branch tube 40 to increase the fluid flow velocity on the side of the delivery cavity 210 close to the branch tube 40.

[0050] To improve the ease of operation of drug delivery devices, such as Figure 7 and Figure 8 As shown, a drug mixing chamber 60 can be provided on the branch tube 40. A piston 610 is provided in the drug mixing chamber 60. The space on the distal side of the piston 610 in the drug mixing chamber 60 is used to store the therapeutic drug or fluid containing the drug. The space on the proximal side of the piston 610 in the drug mixing chamber 60 is used to communicate with a pressure source. The pressure source provides driving pressure to push the piston 610 to move along the drug mixing chamber 60, pushing the therapeutic drug or fluid in the drug mixing chamber 60 into the buffer chamber 50, and then spraying it onto the inner wall of the blood vessel through the delivery channel 210, the expandable unit 30 and the delivery port.

[0051] In some embodiments, solid drugs can be stored in the space on the distal side of the piston 610 within the mixing chamber 60 to facilitate long-term storage of the drug's efficacy within the mixing chamber 60. A three-way valve 70 is provided on the branch pipe 40, located between the mixing chamber 60 and the buffer chamber 50. The first port 710 of the three-way valve 70 corresponds to the mixing chamber 60, the second port 720 corresponds to the buffer chamber 50, and the third port 730 corresponds to the external space. When needed, rotating the three-way valve 70 connects the first port 710 and the third port 730, allowing the user to dispense the liquid (liquid...) At least one of physiological saline, purified water, and contrast agent is injected into the mixing chamber 60 to allow the liquid and solid drugs to mix evenly, forming a mixture in the mixing chamber 60. The three-way valve 70 connects the first port 710 and the second port 720, and the negative pressure source is activated. The piston 610 is pushed to push the mixture to the expandable unit 30 under a preset pressure, forcing the expandable unit 30 to expand in size and allowing the periphery of the expandable unit 30 to come into close contact with the inner wall of the blood vessel. Then, the mixture is sprayed from the micropores 310 onto the inner wall of the blood vessel, allowing the drug to act on the inner wall of the blood vessel and form a stent on the inner wall of the blood vessel, thereby achieving the healing and repair of the blood vessel and achieving the therapeutic effect.

[0052] Specifically, along the fluid flow direction, the fluid flow cross-sectional area of ​​the buffer cavity 50 is larger than that of the conveying cavity 210, so as to increase the fluid velocity in the conveying cavity 210.

[0053] It should be noted that the drug also includes a carrier, on which the therapeutic drug and silk fibroin are loaded. The therapeutic drug is a pure drug or a nanoparticle formed with other components. Nanoparticles include micelles, liposomes, nanocrystals, dendritic molecular carriers, polymer nanoparticles, etc. The active pharmaceutical ingredients are rapamycin or its derivatives, ABT-578, zotaolimus, everolimus, biolimus A9, deforolimus (also known as rapamycin-42 (dimethylphospholipase)), temsirolimus, tacrolimus, pimcrolimus, nitric oxide synthase, C3 exoenzyme, RhoA inhibitor, tubulusin, A3 agonist, CB2 agonist, 17-AAG, Hsp90 antagonist, tyrosine phosphorylation inhibitors, cathepsin S inhibitors, paclitaxel or its derivatives, paclitaxel, docetaxel, corticosteroids, glucocorticoids, dexamethasone, ceramide, dimethylsphingosine, ether-linked diglycerides, ether-linked phosphatidic acids, dihydrosphinganines, estrogens, takil, and takil analogs. Analogs), Actinomycin D, prostaglandins, vitamin A, probucol, batimastat, statins, Trapidil, mitomycin C and cytochalasin B, cytotoxic substances, ethanol, chemotherapeutic agents, sclerosing agents, gene therapy agents, anti-angiogenic agents, antibodies, or any other agents considered effective in the treatment of tumors.

[0054] The photosensitizing compound is a standalone photosensitizer, crosslinker, and / or a combination with a carrier, and can be in any form. For example, it can be lyophilized, non-lyophilized, microencapsulated, nanoencapsulated (e.g., micelles, liposomes, nanocrystals, dendritic molecular carriers, polymer nanoparticles, etc.), protein-bound, freeze-dried, and / or can be provided in the form of tablets, gels, capsules, powders, pastes, creams, ointments, or solutions;

[0055] The photosensitive crosslinking agent is a naphthalimide compound and / or a naphthalimide hydrophilic derivative, camphorquinone and / or a camphorquinone hydrophilic derivative, riboflavin, riboflavin sodium phosphate, rose red, curcumin, or eosin Y.

[0056] Optionally, the photosensitizing compound may further include a photosensitizing synergist to enhance photoinitiation efficiency. The photosensitizing synergist includes, but is not limited to, diphenyliodonium hexafluorophosphate, ethyl p-dimethylaminobenzoate, potassium persulfate, sodium persulfate, and ammonium persulfate. The mass ratio of the photosensitizing synergist to the photosensitizer crosslinking agent is 5:1 to 0.02:1.

[0057] Furthermore, the drug delivery device of this embodiment targets tissue within a body cavity. This body cavity can be a vascular or non-vascular cavity such as an artery, vein, lacrimal duct, airway, prostate, nostril, sinus, ear canal, bile duct, or urethra, representing a diseased area. The drug delivery device of this application is also applicable to cancers located in other body cavities, delivering therapeutic agents from outside the tumor to the tumor site. For example, it has clinical applications in the treatment of cancers of the mouth, nose, pharynx, lungs, esophagus, stomach, intestines, colon, pancreas, rectum, cervix, uterus, and prostate.

[0058] Example 2:

[0059] This application provides a medical device including a pressure source and the drug delivery device of Embodiment 1, wherein the pressure source is connected to the proximal end of the branch tube 40.

[0060] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A drug delivery device, characterized in that, include An inner tube, the distal end of which is provided with an expandable unit, and the expandable unit is provided with a conveying port; The outer tube is sleeved on the inner tube, and the gap between the outer tube and the inner tube forms a delivery cavity. The distal end of the outer tube penetrates the proximal end of the expandable unit, and the distal end face of the outer tube corresponds to the middle part of the expandable unit. The distal end of the delivery cavity is connected to the interior of the expandable unit. A branch pipe, which is connected to the proximal end of the delivery cavity.

2. The drug delivery device as described in claim 1, characterized in that, The delivery port consists of multiple micropores disposed on the expandable unit.

3. The drug delivery device as described in claim 2, characterized in that, The pore size of the micropores is 2μm to 100μm.

4. The drug delivery device as described in claim 2, characterized in that, The density of micropores on the expandable unit is 0.5 pores / cm². 2 ~500 holes / cm 2 .

5. The drug delivery device according to any one of claims 1 to 4, characterized in that, The inner tube and the outer tube may be coaxial or non-coaxial.

6. The drug delivery device as described in claim 5, characterized in that, The outer tube has a buffer cavity at its proximal end, and the branch tube is connected to the proximal end of the delivery channel through the buffer cavity.

7. The drug delivery device as described in claim 6, characterized in that, The cross-section of the buffer cavity is a closed annular structure or a semi-closed annular structure; And / or, the cross-section of the delivery cavity is a closed annular structure or a semi-closed annular structure.

8. The drug delivery device as described in claim 6, characterized in that, The branch pipe is provided with a mixing chamber, and a piston is provided inside the mixing chamber.

9. The drug delivery device as described in claim 8, characterized in that, A three-way valve is installed on the branch pipe, and the three-way valve is located between the mixing chamber and the buffer chamber.

10. A medical device, characterized in that, Includes the drug delivery device according to any one of claims 1 to 9.

Images